E. Nelli

A phase 2 study of bortezomib, cyclophosphamide, pegylated liposomal doxorubicin and dexamethasone for newly diagnosed multiple myeloma

N. Burwick, P. Becker, W. Bensinger, 2016, Blood Cancer Journal.